AR009428A1 - Proceso para mejorar la permeacion en la piel de un compuesto activo farmacologicamente, aplicado topicamente, en el cual de otra manera tiene unavelocidad baja de penetracion en la piel; dispositivos con compartimientos y montaje utiles en dicho proceso. - Google Patents

Proceso para mejorar la permeacion en la piel de un compuesto activo farmacologicamente, aplicado topicamente, en el cual de otra manera tiene unavelocidad baja de penetracion en la piel; dispositivos con compartimientos y montaje utiles en dicho proceso.

Info

Publication number
AR009428A1
AR009428A1 ARP970105339A ARP970105339A AR009428A1 AR 009428 A1 AR009428 A1 AR 009428A1 AR P970105339 A ARP970105339 A AR P970105339A AR P970105339 A ARP970105339 A AR P970105339A AR 009428 A1 AR009428 A1 AR 009428A1
Authority
AR
Argentina
Prior art keywords
skin
drug
permeation
formulation
penetration
Prior art date
Application number
ARP970105339A
Other languages
English (en)
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AR009428A1 publication Critical patent/AR009428A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Proceso y medios tales como un dispositivo con compartimientos o un montaje de distribucion o dispositivo transdérmico que comprende capas de respaldo (2),formulacion con fármaco (4), formulacion con mejorador de permeacion (6), membranasepara dora para romper por presion (8) membrana de difusion (10),adhesivo (12) y recubrimiento de liberacion (14), para mejorar la permeacion epidérmica, transdérmica y dérmica de un agente activo farmacologicamente,aplicado topicamente (por ej.un fárm aco o un medicamento tal como: esteroide, aspirina, fenil butazona, inhibidor enzimáticos, entre otros), el cual tieneuna velocidad baja de penetracion en la piel en la ausencia de un mejorador de la permeacion y el cual es inestable y sedegrada d urante el almacenamiento alargo plazo con los mejoradores de la permeacion particulares (tales como: alcoholes, alcoholes grasos y sus ésteres, entre otros). Una primeracomposicion que contiene un fármaco, una sal del mismo, underivado químico o formulacion del mismo en un vehículo aceptable dermatologicamente y unasegunda composicion que contiene un mejorador de la permeacion de un vehículo aceptable. Las composiciones están separadas físicamente hasta la aplicacionauna superficie de l cuerpo o de la cara y son aplicables topicamente, ya sea al mismo tiempo o secuencialmente dentro del transcurso de un período detiempo breve una de la otra, y mezcladas o combinadas para formar una composicion activafinal sobre la pie l. Permite que una cantidad de fármacoefectiva terapéuticamente sea suministrada hacia la piel y a la circulacion sistemática, por la accion del mejorador de la permeacion en la composicionactiva en el punto de uso.
ARP970105339A 1996-11-18 1997-11-14 Proceso para mejorar la permeacion en la piel de un compuesto activo farmacologicamente, aplicado topicamente, en el cual de otra manera tiene unavelocidad baja de penetracion en la piel; dispositivos con compartimientos y montaje utiles en dicho proceso. AR009428A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/751,293 US6019988A (en) 1996-11-18 1996-11-18 Methods and compositions for enhancing skin permeation of drugs using permeation enhancers, when drugs and/or permeation enhancers are unstable in combination during long-term storage

Publications (1)

Publication Number Publication Date
AR009428A1 true AR009428A1 (es) 2000-04-12

Family

ID=25021358

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP970105339A AR009428A1 (es) 1996-11-18 1997-11-14 Proceso para mejorar la permeacion en la piel de un compuesto activo farmacologicamente, aplicado topicamente, en el cual de otra manera tiene unavelocidad baja de penetracion en la piel; dispositivos con compartimientos y montaje utiles en dicho proceso.

Country Status (14)

Country Link
US (1) US6019988A (es)
EP (1) EP0857488B1 (es)
KR (1) KR19980042501A (es)
CN (1) CN1152672C (es)
AR (1) AR009428A1 (es)
AT (1) ATE271393T1 (es)
AU (1) AU742996B2 (es)
BR (1) BR9705487A (es)
CA (1) CA2220377A1 (es)
DE (1) DE69729932T2 (es)
ES (1) ES2225926T3 (es)
MX (1) MX9708722A (es)
NZ (1) NZ329184A (es)
ZA (1) ZA9710267B (es)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050276836A1 (en) * 1997-06-11 2005-12-15 Michelle Wilson Coated vaginal devices for vaginal delivery of therapeutically effective and/or health-promoting agents
US6306383B1 (en) * 1998-09-16 2001-10-23 Wilson T Crandall Method for topical treatment of scars with protein kinase C inhibitors
CA2389865A1 (en) * 1999-11-04 2001-05-10 Xel Herbaceuticals Transdermal administration of huperzine
US6562368B2 (en) * 1999-12-16 2003-05-13 Dermatrends, Inc. Transdermal administration of oxybutynin using hydroxide-releasing agents as permeation enhancers
US6582724B2 (en) * 1999-12-16 2003-06-24 Dermatrends, Inc. Dual enhancer composition for topical and transdermal drug delivery
US6673363B2 (en) * 1999-12-16 2004-01-06 Dermatrends, Inc. Transdermal and topical administration of local anesthetic agents using basic enhancers
US6562370B2 (en) * 1999-12-16 2003-05-13 Dermatrends, Inc. Transdermal administration of steroid drugs using hydroxide-releasing agents as permeation enhancers
US6602912B2 (en) 2000-06-30 2003-08-05 Dermatrends, Inc. Transdermal administration of phenylpropanolamine
US6565879B1 (en) * 1999-12-16 2003-05-20 Dermatrends, Inc. Topical and transdermal administration of peptidyl drugs with hydroxide-releasing agents as skin permeation enhancers
US6586000B2 (en) * 1999-12-16 2003-07-01 Dermatrends, Inc. Hydroxide-releasing agents as skin permeation enhancers
US6645520B2 (en) 1999-12-16 2003-11-11 Dermatrends, Inc. Transdermal administration of nonsteroidal anti-inflammatory drugs using hydroxide-releasing agents as permeation enhancers
US6719997B2 (en) 2000-06-30 2004-04-13 Dermatrends, Inc. Transdermal administration of pharmacologically active amines using hydroxide-releasing agents as permeation enhancers
US6558695B2 (en) * 1999-12-16 2003-05-06 Dermatrends, Inc. Topical and transdermal administration of peptidyl drugs using hydroxide releasing agents as permeation enhancers
US20030104041A1 (en) * 1999-12-16 2003-06-05 Tsung-Min Hsu Transdermal and topical administration of drugs using basic permeation enhancers
US6562369B2 (en) * 1999-12-16 2003-05-13 Dermatrends, Inc. Transdermal administration of androgenic drugs hydroxide-releasing agents as permeation enhancers
AU2001280057A1 (en) * 2000-08-07 2002-02-18 Transdermics Ltd. Pharmaceutical carriers and compositions for transdermal drug delivery
US20040092494A9 (en) * 2000-08-30 2004-05-13 Dudley Robert E. Method of increasing testosterone and related steroid concentrations in women
US6503894B1 (en) * 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
US20040002482A1 (en) * 2000-08-30 2004-01-01 Dudley Robert E. Androgen pharmaceutical composition and method for treating depression
US20020198215A1 (en) * 2000-10-23 2002-12-26 Lino Tavares Terazosin transdermal device and methods
US6635274B1 (en) * 2000-10-27 2003-10-21 Biochemics, Inc. Solution-based transdermal drug delivery system
EP1351685B1 (en) * 2001-01-19 2008-02-27 Johnson & Johnson Consumer Companies, Inc. Stabilized formulation of selective ligands of retinoic acid gamma-receptors
US20030104976A1 (en) * 2001-07-23 2003-06-05 Gudarz Davar Analgesic methods using endothelin receptor ligands
US20030021835A1 (en) * 2001-07-24 2003-01-30 Ancel Surgical R&D, Inc. Medical patch with burstable partition
US20030166732A1 (en) * 2002-02-27 2003-09-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ambroxol for the treatment of painful conditions in the mouth and pharyngeal cavity
EP1509209A1 (en) * 2002-05-23 2005-03-02 UMD, Inc. Compositions and method for transmucosal drug delivery and cryoprotection
CN1207005C (zh) * 2002-10-31 2005-06-22 威世药业(如皋)有限公司 含生物活性物质的兔皮和其用途
PL2106805T3 (pl) * 2003-03-21 2011-10-31 Nexmed Holdings Inc Przeciwgrzybicza powłoka na paznokcie
US20050036953A1 (en) * 2003-08-13 2005-02-17 Moshe Arkin Topical compositions of ammonium lactate
US20050042182A1 (en) * 2003-08-13 2005-02-24 Moshe Arkin Topical compositions of urea
US20050037040A1 (en) * 2003-08-13 2005-02-17 Moshe Arkin Topical compositions of urea and ammonium lactate
US20050042268A1 (en) * 2003-07-16 2005-02-24 Chaim Aschkenasy Pharmaceutical composition and method for transdermal drug delivery
US20050025833A1 (en) * 2003-07-16 2005-02-03 Chaim Aschkenasy Pharmaceutical composition and method for transdermal drug delivery
US20050020552A1 (en) * 2003-07-16 2005-01-27 Chaim Aschkenasy Pharmaceutical composition and method for transdermal drug delivery
US20050014823A1 (en) * 2003-07-17 2005-01-20 Soderlund Patrick L. Topical anesthetic composition and method of administration
EP1677747A1 (en) * 2003-10-31 2006-07-12 The Procter & Gamble Company Method of providing a blended composition
ATE493973T1 (de) 2004-06-04 2011-01-15 Teva Pharma Irbesartan enthaltende pharmazeutische zusammensetzung
DE102004062614B4 (de) * 2004-12-24 2011-12-29 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System mit aktivierbarer Übersättigung und kontrollierter Permeationförderung sowie Verfahren zu dessen Herstellung
US20080206316A1 (en) * 2005-01-27 2008-08-28 Colin Barrow Chromium-Fatty Acid Compounds and Methods of Making and Using Thereof
US20070088012A1 (en) * 2005-04-08 2007-04-19 Woun Seo Method of treating or preventing type-2 diabetes
WO2007005469A2 (en) * 2005-06-29 2007-01-11 Jr Chem, Llc Method of enhanced benzoyl peroxide application
US9968120B2 (en) * 2006-05-17 2018-05-15 Dsm Nutritional Products Ag Homogenized formulations containing microcapsules and methods of making and using thereof
US20070065494A1 (en) * 2005-08-03 2007-03-22 Watson Laboratories, Inc. Formulations and Methods for Enhancing the Transdermal Penetration of a Drug
PT1937276E (pt) 2005-10-12 2013-02-21 Besins Healthcare Luxembourg Gel de testosterona melhorado e método para a sua utilização
DE102005050431A1 (de) 2005-10-21 2007-04-26 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System zur Verabreicherung lipophiler und/oder wenig hautpermeabler Wirkstoffe
GB0524121D0 (en) * 2005-11-26 2006-01-04 Namibia Medical Invest Pty Ltd Patch
CA2645073A1 (en) * 2006-03-08 2007-09-13 Nuviance, Inc. Transdermal drug delivery compositions and topical compositions for application on the skin
US20100055281A1 (en) * 2006-04-07 2010-03-04 Ocean Nutrition Canada Limited Emulsions and Microcapsules With Substances Having Low Interfacial Tension, Methods of Making and Using Thereof
MX306461B (es) * 2006-06-05 2013-01-07 Ocean Nutrition Canada Ltd Microcapsulas con cubiertas mejoradas
US20090304776A1 (en) * 2008-06-06 2009-12-10 Totada Shantha Transmucosal delivery of therapeutic agents and methods of use thereof
EP2654638A4 (en) * 2010-12-20 2014-07-02 Polytherapeutics Inc COMPOSITION FOR TRANSDERMAL ADMINISTRATION OF NON-STEROIDAL ANTI-INFLAMMATORY DRUG
RU2015144149A (ru) * 2013-03-15 2017-04-21 Интермьюн, Инк. Протеомные маркеры илф
TWI593411B (zh) 2013-04-30 2017-08-01 徐懷山 組合物於製備抑制雄性素受體有關之功能及治療雄性素 受體相關之疾病的藥物之用途
EP3236903B1 (en) 2014-12-23 2021-04-21 Intellectual Property Associates, LLC Methods and formulations for transdermal administration
US11337745B2 (en) 2018-05-29 2022-05-24 Ilooda Co., Ltd. Device for treatment of acne and control method of the same
US20220008110A1 (en) * 2018-10-04 2022-01-13 Miraki Innovation Think Tank Llc Methods of treating subcutaneous fat layers
KR102256054B1 (ko) 2019-03-21 2021-05-25 (주)심플스틱 골드입자를 이용한 여드름 개선방법

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4497794A (en) * 1980-12-08 1985-02-05 Dermik Laboratories, Inc. Erythromycin/benzoyl peroxide composition for the treatment of acne
US4379454A (en) * 1981-02-17 1983-04-12 Alza Corporation Dosage for coadministering drug and percutaneous absorption enhancer
US4931283A (en) * 1983-12-22 1990-06-05 American Home Products Corp. (Del) Menthol enhancement of transdermal drug delivery
US4592487A (en) * 1985-07-03 1986-06-03 Simon Gilbert I Dentifrices
FR2586913B1 (fr) * 1985-09-10 1990-08-03 Oreal Procede pour former in situ une composition constituee de deux parties conditionnees separement et ensemble distributeur pour la mise en oeuvre de ce procede
US4666441A (en) * 1985-12-17 1987-05-19 Ciba-Geigy Corporation Multicompartmentalized transdermal patches
EP0252459A1 (en) * 1986-07-07 1988-01-13 Schering Corporation Compartmentalized transdermal delivery system
US4911707A (en) * 1987-02-13 1990-03-27 Ciba-Geigy Corporation Monolithic user-activated transdermal therapeutic system
US5422119A (en) * 1987-09-24 1995-06-06 Jencap Research Ltd. Transdermal hormone replacement therapy
US5028431A (en) * 1987-10-29 1991-07-02 Hercon Laboratories Corporation Article for the delivery to animal tissue of a pharmacologically active agent
AU5190790A (en) * 1989-02-23 1990-09-26 University Of Utah, The Percutaneous drug delivery system
US5223262A (en) * 1989-02-23 1993-06-29 University Of Utah Transdermal delivery system utilizing one way membranes
US5156846A (en) * 1989-02-23 1992-10-20 University Of Utah Percutaneous drug delivery system
US4956171A (en) * 1989-07-21 1990-09-11 Paco Pharmaceutical Services, Inc. Transdermal drug delivery using a dual permeation enhancer and method of performing the same
GB9025711D0 (en) * 1990-11-27 1991-01-09 Beecham Group Plc Topical composition
US5174475A (en) * 1991-03-26 1992-12-29 Glaxo Inc. Sequential dosing of antifungal and antiinflammatory compositions
US5326566A (en) * 1991-05-17 1994-07-05 Bristol-Myers Squibb Company Use of dibutyl adipate and isopropyl myristate in topical and transdermal products
US5436369A (en) * 1993-06-16 1995-07-25 Bristol-Myers Squibb Company Alicyclic phospholipase A2 inhibitors
ES2074030B1 (es) * 1994-01-31 1996-02-01 S A L V A T Lab Sa Composiciones portadoras, autocalentadoras y aplicables en terapeutica por via topica.
US5538732A (en) * 1994-04-12 1996-07-23 Creative Products Resource, Inc. Medicated applicator sheet for topical drug delivery
DE4435805A1 (de) * 1994-10-06 1996-04-11 Knoll Ag Zweikomponenten-Creme

Also Published As

Publication number Publication date
AU4520097A (en) 1998-05-21
EP0857488A2 (en) 1998-08-12
DE69729932D1 (de) 2004-08-26
NZ329184A (en) 1999-03-29
AU742996B2 (en) 2002-01-17
ES2225926T3 (es) 2005-03-16
BR9705487A (pt) 1999-04-06
ATE271393T1 (de) 2004-08-15
EP0857488A3 (en) 1999-08-25
MX9708722A (es) 1998-07-31
US6019988A (en) 2000-02-01
CN1190001A (zh) 1998-08-12
DE69729932T2 (de) 2005-08-25
ZA9710267B (en) 1999-05-13
CN1152672C (zh) 2004-06-09
KR19980042501A (ko) 1998-08-17
CA2220377A1 (en) 1998-05-18
EP0857488B1 (en) 2004-07-21

Similar Documents

Publication Publication Date Title
AR009428A1 (es) Proceso para mejorar la permeacion en la piel de un compuesto activo farmacologicamente, aplicado topicamente, en el cual de otra manera tiene unavelocidad baja de penetracion en la piel; dispositivos con compartimientos y montaje utiles en dicho proceso.
US20240252647A1 (en) Compositions, gels and foams with rheology modulators and uses thereof
AR021539A1 (es) Preparaciones topicas anhidras para la piel
US6455065B1 (en) Therapeutic method for treating acne or isolated pimples and adhesive patch therefor
US20050187212A1 (en) Pharmaceutical composition for topical delivery of meloxicam
ES2058109T3 (es) Un procedimiento para la preparacion de una composicion farmaceutica antimicrobiana topica.
AR033808A1 (es) Una composicion topica de anestesia local y los parches y los envases que la contienen
ES2028074T3 (es) Activacion por humedad de un sistema de suministro transdermico de farmacos.
EP0857488A1 (en) Methods and compositions for enhancing skin permeation of drugs using permeation enhancers
AR019997A1 (es) Sistema de administracion topica para agentes activos
DE69011131D1 (de) Wirkstoff enthaltende vorrichtung zur langzeitabgabe.
WO1993008841A1 (en) Skin permeation enhancer compositions
EP1323430A3 (en) Composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels
BR9713492A (pt) ésteres de ácido graxo de ácido glicólico e seus sais como realçadores de permeação
AR002636A1 (es) Dispositivo de afeitar en humedo que comprende un compuesto auxiliar con un agente refrescante no volatil
HU217544B (hu) Hatóanyagként 4-bifenil-ecetsavat tartalmazó, helyileg adagolandó gyógyászati készítmény, és eljárás a készítmény előállítására
PE20050919A1 (es) Agente endoparasiticida para administracion topica
ES2200352T3 (es) Preparaciones estables de uso externo a base de acido acetilsalicilico.
BR0007360A (pt) Composição de liberação controlada
ES2042564T3 (es) Composiciones por via topica penetrantes mejoradas para aumentar el crecimiento del cabello.
PT89892B (pt) Processo para a preparacao de composicoes farmaceuticas bactericidas para o tratamento topico externo do acne contendo paraclorometaxilenci, peroxido de benzoilo, triclosan, enxofre ou acido salicilico ou misturas dos mesmos
PE20040548A1 (es) Lamina revestida de adhesivo para administracion dermica de un inhibidor selectivo de ciclooxigenasa-2
AR064262A1 (es) Composiciones farmaceuticas liquidas que comprenden un compuesto bisfosfonato
ES2264927T3 (es) Dispositivo para la entrega de sustancias activas cosmeticas.
FI961435A (fi) Transdermaalinen terapeuttinen järjestelmä joka sisältää oktyylidodekanolia kiteytymisen inhibiittoreina

Legal Events

Date Code Title Description
FB Suspension of granting procedure